Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial.

Lai WeiTingting ZhaoJi ZhangQing MaoGuozhong GongYongtao SunYongping ChenMaorong WangDeming TanZuojiong GongBaosen LiJunqi NiuShuchen LiHuanyu GongLiyun ZouWei ZhouZhengcai JiaYan TangLei FeiYang HuXiaoyun ShangJunfeng HanBei ZhangYuzhang Wu

Published in: Hepatology (Baltimore, Md.) (2021)

Among HLA-A2-positive patients with progressive CHB, a finite duration of 900 µg εPA-44 monotherapy resulted in significantly higher HBeAg seroconversion rate than placebo and sustained off-treatment effect. A phase 3 trial is ongoing (ChiCTR2100043708).

Keyphrases

hepatitis b virus
combination therapy
multiple sclerosis
open label
randomized controlled trial
double blind
smoking cessation
placebo controlled